肿瘤细胞治疗研究
英文原题：Advancements in the design and function of bispecific CAR-T cells targeting B Cell-Associated tumor antigens.
单靶点CAR-T在治疗B细胞肿瘤方面取得了显著成功，有效改善了患者的预后。
单靶点CAR-T在治疗B细胞肿瘤方面已取得显著成功，有效改善了患者预后。然而，患者复发率仍高于百分之五十，主要归因于抗原逃逸和CAR-T细胞免疫持久性降低。近年来，双特异性CAR-T细胞疗法引起了大量关注，每年研究文章和临床应用数量不断增加。本文对近年来双特异性CAR-T设计方面具有影响力的研究进行了全面综述，探讨了其在疾病分类、靶向抗原和CAR设计方面对双特异性CAR-T疗效的影响。本文探讨了B-ALL、NHL和MM中抗原靶向的显著差异，并分析了CAR scFv、跨膜区、铰链区和共刺激区设计如何影响Bi-CAR-T在不同肿瘤中的疗效。本文所提供的总结旨在为设计新型且改进的CAR-T提供参考，从而促进B细胞恶性肿瘤更高效的治疗。
Single-targeted CAR-T has exhibited notable success in treating B-cell tumors, effectively improving patient outcomes. However, the recurrence rate among patients remains above fifty percent, primarily attributed to antigen escape and the diminished immune persistence of CAR-T cells. Over recent years, there has been a surge of interest in bispecific CAR-T cell therapies, marked by an increasing number of research articles and clinical applications annually. This paper undertakes a comprehensive review of influential studies on the design of bispecific CAR-T in recent years, examining their impact on bispecific CAR-T efficacy concerning disease classification, targeted antigens, and CAR design. Notable distinctions in antigen targeting within B-ALL, NHL, and MM are explored, along with an analysis of how CAR scFv, transmembrane region, hinge region, and co-stimulatory region design influence Bi-CAR-T efficacy across different tumors. The summary provided aims to serve as a reference for designing novel and improved CAR-Ts, facilitating more efficient treatment for B-cell malignant tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
